Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AGIO NASDAQ:COGT NASDAQ:KYMR NASDAQ:PTGX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAGIOAgios Pharmaceuticals$27.80+1.0%$29.70$22.24▼$46.00$1.65B0.581.02 million shs89,230 shsCOGTCogent Biosciences$34.790.0%$36.35$4.55▼$43.73$5.94B0.372.06 million shs163,236 shsKYMRKymera Therapeutics$85.56+1.1%$84.25$28.06▼$103.00$7.04B2.06689,560 shs52,032 shsPTGXProtagonist Therapeutics$97.58-1.3%$99.40$42.85▼$107.84$6.28B1.89768,980 shs53,751 shsDon't wait for the SpaceX IPOThe space race is growing fast, and you don’t have to wait for SpaceX to go public to invest. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAGIOAgios Pharmaceuticals+2.04%-1.68%-21.59%+3.77%-2.27%COGTCogent Biosciences-3.12%-2.79%-2.33%-6.18%+641.47%KYMRKymera Therapeutics-1.89%+4.39%-0.55%+6.33%+190.72%PTGXProtagonist Therapeutics-4.92%-0.12%-4.72%+17.00%+129.40%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAGIOAgios Pharmaceuticals$27.80+1.0%$29.70$22.24▼$46.00$1.65B0.581.02 million shs89,230 shsCOGTCogent Biosciences$34.790.0%$36.35$4.55▼$43.73$5.94B0.372.06 million shs163,236 shsKYMRKymera Therapeutics$85.56+1.1%$84.25$28.06▼$103.00$7.04B2.06689,560 shs52,032 shsPTGXProtagonist Therapeutics$97.58-1.3%$99.40$42.85▼$107.84$6.28B1.89768,980 shs53,751 shsDon't wait for the SpaceX IPOThe space race is growing fast, and you don’t have to wait for SpaceX to go public to invest. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAGIOAgios Pharmaceuticals+2.04%-1.68%-21.59%+3.77%-2.27%COGTCogent Biosciences-3.12%-2.79%-2.33%-6.18%+641.47%KYMRKymera Therapeutics-1.89%+4.39%-0.55%+6.33%+190.72%PTGXProtagonist Therapeutics-4.92%-0.12%-4.72%+17.00%+129.40%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAGIOAgios Pharmaceuticals 2.45Hold$41.5649.48% UpsideCOGTCogent Biosciences 2.86Moderate Buy$43.7325.69% UpsideKYMRKymera Therapeutics 2.96Moderate Buy$118.1038.03% UpsidePTGXProtagonist Therapeutics 2.80Moderate Buy$113.6916.51% UpsideCurrent Analyst Ratings BreakdownLatest AGIO, KYMR, PTGX, and COGT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/6/2026PTGXProtagonist Therapeutics The Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingNeutral$110.005/6/2026COGTCogent Biosciences HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$55.005/6/2026PTGXProtagonist Therapeutics CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform5/6/2026KYMRKymera Therapeutics Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$106.005/6/2026PTGXProtagonist Therapeutics Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetMarket Outperform$120.00 ➝ $137.005/6/2026PTGXProtagonist Therapeutics WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$112.00 ➝ $118.004/30/2026KYMRKymera Therapeutics Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight$119.004/30/2026AGIOAgios Pharmaceuticals Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$39.00 ➝ $36.004/21/2026KYMRKymera Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/21/2026AGIOAgios Pharmaceuticals Bank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$44.00 ➝ $41.004/20/2026AGIOAgios Pharmaceuticals HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$65.00 ➝ $50.00(Data available from 5/8/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAGIOAgios Pharmaceuticals$54.03M30.60N/AN/A$18.65 per share1.49COGTCogent BiosciencesN/AN/AN/AN/A$3.18 per shareN/AKYMRKymera Therapeutics$39.21M179.49N/AN/A$18.72 per share4.57PTGXProtagonist Therapeutics$74.06M84.73N/AN/A$10.19 per share9.58Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAGIOAgios Pharmaceuticals-$412.78M-$7.25N/AN/AN/A-639.84%-34.11%-31.66%N/ACOGTCogent Biosciences-$328.94M-$2.17N/AN/AN/AN/A-104.27%-54.64%N/AKYMRKymera Therapeutics-$311.35M-$3.57N/AN/AN/A-611.94%-24.71%-22.05%N/APTGXProtagonist Therapeutics-$130.15M-$1.81N/AN/AN/A-154.88%-17.76%-16.47%N/ALatest AGIO, KYMR, PTGX, and COGT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/5/2026Q1 2026COGTCogent Biosciences-$0.53-$0.53N/A-$0.53N/AN/A5/5/2026Q1 2026PTGXProtagonist Therapeutics-$0.5004$0.05+$0.5504$0.05$11.70 million$56.37 million4/30/2026Q1 2026KYMRKymera Therapeutics-$0.89-$0.71+$0.18-$0.71$8.27 million$34.37 million4/29/2026Q1 2026AGIOAgios Pharmaceuticals-$1.81-$1.69+$0.12-$1.69$13.30 million$20.75 million2/26/2026Q4 2025KYMRKymera Therapeutics-$0.77-$0.97-$0.20-$0.97$14.80 million$2.87 million2/25/2026Q4 2025PTGXProtagonist Therapeutics-$0.53-$0.69-$0.16-$0.69$14.92 million$7.44 million2/17/2026Q4 2025COGTCogent Biosciences-$0.51-$0.55-$0.04-$0.61N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAGIOAgios PharmaceuticalsN/AN/AN/AN/AN/ACOGTCogent BiosciencesN/AN/AN/AN/AN/AKYMRKymera TherapeuticsN/AN/AN/AN/AN/APTGXProtagonist TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAGIOAgios PharmaceuticalsN/A14.1913.59COGTCogent Biosciences0.4115.1414.23KYMRKymera TherapeuticsN/A10.8110.81PTGXProtagonist TherapeuticsN/A17.7612.71Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAGIOAgios PharmaceuticalsN/ACOGTCogent BiosciencesN/AKYMRKymera TherapeuticsN/APTGXProtagonist Therapeutics98.63%Insider OwnershipCompanyInsider OwnershipAGIOAgios Pharmaceuticals5.40%COGTCogent Biosciences7.29%KYMRKymera Therapeutics16.01%PTGXProtagonist Therapeutics4.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAGIOAgios Pharmaceuticals39059.47 million56.26 millionOptionableCOGTCogent Biosciences80170.87 million158.35 millionOptionableKYMRKymera Therapeutics17082.26 million69.09 millionOptionablePTGXProtagonist Therapeutics12064.31 million61.15 millionOptionableAGIO, KYMR, PTGX, and COGT HeadlinesRecent News About These CompaniesIs It Too Late To Consider Protagonist Therapeutics (PTGX) After Its 141% One Year Surge?May 7 at 7:32 AM | finance.yahoo.comProtagonist Therapeutics (NASDAQ:PTGX) Given New $137.00 Price Target at Citizens JmpMay 7 at 4:20 AM | americanbankingnews.comProtagonist Therapeutics (NASDAQ:PTGX) Given New $118.00 Price Target at WedbushMay 7 at 4:20 AM | americanbankingnews.comProtagonist Therapeutics: Q1 Earnings SnapshotMay 6 at 4:30 PM | chron.comProtagonist Therapeutics (NASDAQ:PTGX) Price Target Raised to $137.00May 6 at 11:48 AM | marketbeat.comProtagonist Therapeutics (NASDAQ:PTGX) Stock Price Expected to Rise, Wedbush Analyst SaysMay 6 at 8:49 AM | marketbeat.comVanguard Group Inc. Purchases 1,156,461 Shares of Protagonist Therapeutics, Inc. $PTGXMay 6 at 8:14 AM | marketbeat.comProtagonist Therapeutics: Protagonist Reports First Quarter 2026 Financial Results and Provides Corporate UpdateMay 5 at 11:17 PM | finanznachrichten.deProtagonist Therapeutics (NASDAQ:PTGX) Posts Earnings Results, Beats Expectations By $0.70 EPSMay 5 at 7:21 PM | marketbeat.comProtagonist Reports First Quarter 2026 Financial Results and Provides Corporate UpdateMay 5 at 4:05 PM | accessnewswire.comAProtagonist Therapeutics, Inc. (NASDAQ:PTGX) Receives Average Rating of "Moderate Buy" from BrokeragesMay 5 at 2:10 AM | americanbankingnews.comProtagonist Therapeutics, Inc. (NASDAQ:PTGX) Receives Average Rating of "Moderate Buy" from AnalystsMay 5 at 2:07 AM | marketbeat.comProtagonist Therapeutics Inc. (PTGX): Billionaire Tom Steyer Likes Upside Potential of This StockMay 2, 2026 | insidermonkey.com331,164 Shares in Protagonist Therapeutics, Inc. $PTGX Bought by Jennison Associates LLCMay 2, 2026 | marketbeat.comM&T Bank Corp Acquires New Holdings in Protagonist Therapeutics, Inc. $PTGXMay 1, 2026 | marketbeat.comAnalysts Conflicted on These Healthcare Names: Molina Healthcare (MOH), Design Therapeutics (DSGN) and Protagonist Therapeutics (PTGX)April 30, 2026 | theglobeandmail.comPictet Asset Management Holding SA Has $46.26 Million Stock Position in Protagonist Therapeutics, Inc. $PTGXApril 30, 2026 | marketbeat.comProtagonist Therapeutics, Inc. $PTGX Shares Sold by Moody Aldrich Partners LLCApril 29, 2026 | marketbeat.comUBS Group AG Acquires 874,013 Shares of Protagonist Therapeutics, Inc. $PTGXApril 29, 2026 | marketbeat.comProtagonist Therapeutics (PTGX) Projected to Post Quarterly Earnings on WednesdayApril 29, 2026 | marketbeat.comProtagonist Therapeutics: Protagonist Exercises Rusfertide U.S. Opt-Out Right Under Takeda CollaborationApril 29, 2026 | finanznachrichten.deNew MarketBeat Followers Over TimeMedia Sentiment Over TimeAGIO, KYMR, PTGX, and COGT Company DescriptionsAgios Pharmaceuticals NASDAQ:AGIO$27.80 +0.27 (+0.98%) As of 11:06 AM Eastern This is a fair market value price provided by Massive. Learn more.Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.Cogent Biosciences NASDAQ:COGT$34.79 0.00 (0.00%) As of 11:06 AM Eastern This is a fair market value price provided by Massive. Learn more.Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.Kymera Therapeutics NASDAQ:KYMR$85.56 +0.93 (+1.09%) As of 11:06 AM Eastern This is a fair market value price provided by Massive. Learn more.Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company develops STAT6, a Type 2 inflammation in allergic diseases; and TYK2, a treatment for inflammatory bowel disease, psoriasis, psoriatic arthritis, and lupus. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.Protagonist Therapeutics NASDAQ:PTGX$97.58 -1.27 (-1.29%) As of 11:06 AM Eastern This is a fair market value price provided by Massive. Learn more.Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company has a license and collaboration agreement with Takeda to commercialize rusfertide; and JNJ Innovative Medicines to co-develop Interleukin-23 receptor antagonist compound JNJ-2113. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Dutch Bros Q1 Earnings: The Newest Starbucks Rival Faces Its First Big Reality Check The AI Fear Around Datadog Stock May Have Been Completely Wrong Amprius Technologies Ups the Voltage on Forward Outlook Why Lam Research Still Looks Like a Buy After a 300% Rally Wells Fargo’s Comeback Is Real—But Not Risk-Free IonQ Just Posted a Breakout Quarter—But 1 Problem Remains SLB’s Tough Quarter Masks a Powerful Long-Term Shift Super Micro Surges Over 20% as Margins Soar, Sales Fall Short Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
